Zobrazeno 1 - 10
of 215
pro vyhledávání: '"David Schrama"'
Autor:
Jonas Wohlfarth, Corinna Kosnopfel, Dominic Faber, Marion Berthold, Claudia Siedel, Melissa Bernhardt, Andreas Schlosser, Tyler Aprati, David Liu, David Schrama, Roland Houben, Dirk Schadendorf, Matthias Goebeler, Svenja Meierjohann, Bastian Schilling
Publikováno v:
Molecular Oncology, Vol 18, Iss 10, Pp 2449-2470 (2024)
Immunotherapy has achieved tremendous success in melanoma. However, only around 50% of advanced melanoma patients benefit from immunotherapy. Cyclin‐dependent kinase inhibitor 2A (CDKN2A), encoding the two tumor‐suppressor proteins p14ARF and p16
Externí odkaz:
https://doaj.org/article/329322a45f3c4cab9aaa97867023c73c
Autor:
Thilo Gambichler, David Schrama, Riina Käpynen, Sera S. Weyer-Fahlbusch, Jürgen C. Becker, Laura Susok, Florian Kreppel, Nessr Abu Rached
Publikováno v:
Vaccines, Vol 12, Iss 5, p 533 (2024)
Merkel cell carcinoma is a rare, aggressive skin cancer that mainly occurs in elderly and immunocompromised patients. Due to the success of immune checkpoint inhibition in MCC, the importance of immunotherapy and vaccines in MCC has increased in rece
Externí odkaz:
https://doaj.org/article/aca935283e7842faa73199b2bef58659
Autor:
Corinna Kosnopfel, Simone Wendlinger, Heike Niessner, Johannes Siewert, Tobias Sinnberg, Angelika Hofmann, Jonas Wohlfarth, David Schrama, Marion Berthold, Claudia Siedel, Birgit Sauer, Aarthi Jayanthan, Georg Lenz, Sandra E. Dunn, Bastian Schilling, Birgit Schittek
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-14 (2023)
Abstract Background The mitogen-activated protein kinase (MAPK) signaling pathway is frequently hyperactivated in malignant melanoma and its inhibition has proved to be an efficient treatment option for cases harboring BRAFV600 mutations (BRAFMut). H
Externí odkaz:
https://doaj.org/article/0723a98be8b54729b41f40fee5a42d27
Autor:
Veronika Banicka, Marie Christine Martens, Rüdiger Panzer, David Schrama, Steffen Emmert, Lars Boeckmann, Alexander Thiem
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 19, p 11649 (2022)
Defects in DNA repair pathways have been associated with an improved response to immune checkpoint inhibition (ICI). In particular, patients with the nucleotide excision repair (NER) defect disease Xeroderma pigmentosum (XP) responded impressively we
Externí odkaz:
https://doaj.org/article/861559c07af34bdfa338efb90dee3197
Autor:
Alexander Thiem, Sonja Hesbacher, Hermann Kneitz, Teresa di Primio, Markus V. Heppt, Heike M. Hermanns, Matthias Goebeler, Svenja Meierjohann, Roland Houben, David Schrama
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-15 (2019)
Abstract Background Immune checkpoint inhibition and in particular anti-PD-1 immunotherapy have revolutionized the treatment of advanced melanoma. In this regard, higher tumoral PD-L1 protein (gene name: CD274) expression is associated with better cl
Externí odkaz:
https://doaj.org/article/f763bb8e779141d8a8d6767b053ede39
Autor:
Marion Wobser, Alexandra Weber, Amelie Glunz, Saskia Tauch, Kristina Seitz, Tobias Butelmann, Sonja Hesbacher, Matthias Goebeler, René Bartz, Hella Kohlhof, David Schrama, Roland Houben
Publikováno v:
Journal of Hematology & Oncology, Vol 12, Iss 1, Pp 1-16 (2019)
Abstract Background Targeting epigenetic modifiers is effective in cutaneous T cell lymphoma (CTCL). However, there is a need for further improvement of this therapeutic approach. Here, we compared the mode of action of romidepsin (FK228), an establi
Externí odkaz:
https://doaj.org/article/a44783db4f2242dd9008d5dd78ff5fa5
Autor:
Cathrin Ritter, Kaiji Fan, Annette Paschen, Sine Reker Hardrup, Soldano Ferrone, Paul Nghiem, Selma Ugurel, David Schrama, Jürgen C. Becker
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-11 (2017)
Abstract Merkel cell carcinoma (MCC) is a rare and aggressive, yet highly immunogenic skin cancer. The latter is due to its viral or UV-associated carcinogenesis. For tumor progression MCC has to escape the host’s immuno-surveillance, e.g. by loss
Externí odkaz:
https://doaj.org/article/8a93f8dccd0d4f538a485c5193e1806a
Autor:
Thibault Kervarrec, Mahtab Samimi, Serge Guyétant, Bhavishya Sarma, Jérémy Chéret, Emmanuelle Blanchard, Patricia Berthon, David Schrama, Roland Houben, Antoine Touzé
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Merkel cell carcinoma (MCC) is a primary neuroendocrine carcinoma of the skin. This neoplasia features aggressive behavior, resulting in a 5-year overall survival rate of 40%. In 2008, Feng et al. identified Merkel cell polyomavirus (MCPyV) integrati
Externí odkaz:
https://doaj.org/article/87cd8456e5ac4dc8901879c3056672be
Autor:
Alexander Thiem, Hermann Kneitz, Patrick Schummer, Stefan Herz, David Schrama, Roland Houben, Matthias Goebeler, Bastian Schilling, Anja Gesierich
Publikováno v:
Acta Dermato-Venereologica, Vol 97, Iss 10, Pp 1252-1254 (2017)
Externí odkaz:
https://doaj.org/article/4a8168cf0f394e1798e32ba4d0b996df
Publikováno v:
Viruses, Vol 12, Iss 10, p 1162 (2020)
Merkel cell carcinoma (MCC) is an aggressive skin cancer frequently caused by the Merkel cell polyomavirus (MCPyV), and proliferation of MCPyV-positive MCC tumor cells depends on the expression of a virus-encoded truncated Large T antigen (LT) oncopr
Externí odkaz:
https://doaj.org/article/9e218bad0308417fb67a82e312a63b25